HUMAN RECOMBINANT EP1 RECEPTOR
MULTISCREEN™ DIVISION ARRESTED CELL LINE
1 vial (4 x 106) frozen cells
Sigma Freezing Medium (C-6164)
Expression vector containing full-length human PTGER1 cDNA (GenBank accession number NM_000955.2) with FLAG tag sequence at N-terminus
Liquid nitrogen upon receiving
Propagation Medium: DMEM, 10% FBS
Stable for 1-2 days after thawing
Background: EP1 receptor (or PTGER1) is a receptor or prostaglandin E2 (PGE2). The receptor may play a role in the smooth muscle contractile response to PGE2 in various tissues. EP1 receptor transactivates EGFR thus activating Akt, while activation of EGFR by its cognate ligand EGF increased COX-2 expression and PGE2 production. This crosstalk between EP1 and EGFR signaling synergistically promotes cancer cell growth and invasion. Some EP1- specific antagonists inhibit osteoclast formation induced by RANKL from the early stage of osteoclastogenesis.
The Multispan EP1 cell line expresses EP1 cDNA that is identical to GenBank NM_000955.2 except for 1 sense mutation, Thr→Ala at position 70. It has been reported as a natural variant.
Application: Functional assays
Figure 1. Dose-dependent stimulation of calcium flux upon treatment with ligand, measured with MultiscreenTM Calcium 1.0 No Wash Assay Kit (Multispan MSCA01).
Han and Wu (2005) Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of epidermal growth factor receptor and AKT. J Biol Chem 280:24053-24063.
Tsujisawa et al. (2005) SC-19220, antagonist of prostaglandin E2 receptor EP1, inhibits osteoclastogenesis by RANKL. J Bone Miner Res 20:15-22.